Zanubrutinib (Brukinsa)


 CADTH recommends that Brukinsa be reimbursed by public drug plans for the treatment of adult patients with chronic lymphocytic leukemia (CLL) if certain conditions are met.
 should only covered to treat previously untreated CLL whom fludarabine-based is inappropriate or relapsed refractory (r/r) who have received at least 1 prior systemic therapy. Patients receiving in relatively good health (i.e., a performance status, as determined specialist). progressed on Bruton tyrosine kinase (BTK) inhibitor prolymphocytic Richter’s transformation not eligible coverage.
 prescribed clinicians expertise and experience monitoring therapy it associated cost savings programs relative ibrutinib acalabrutinib. disease progression while taking cannot tolerate would continued